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Abstract
Purpose: In this study, the team modeled the biodistribution and the efficiency of two 99m-technetium diethylene triamine penta
acetate (99mTc-DTPA) based radiopharmaceuticals. Methods: The first radiopharmaceutical (DTPA-CNESTEN) is developed at
the laboratories of the radiopharmaceutical production unit of the National Center for Nuclear Energy, Sciences and Technolo-
gies (CNESTEN-Morocco), and the second one is the commercial DTPA (DTPA-ref). Freeze-dried kits were successfully radio-
labeled (radiochemical purity >95%) with the 99m Tc. Then drugs were injected to male BALB/c mice. In each 2 min, 5 min, 15
min, 1 h and 2 h time points after injections we evaluate tissue’s distributions characteristics. At the end, an automatic modeling
of the data were recorded from thyroid, blood and urinary excretion kinetics and biodistribution in mice using both DTPA kits.
The study aimed to extract the parameters of the function used to fit the recorded data. Results and Conclusion: the team con-
cluded that the biodistribution of 99mTc-DTPA can be modeled using a combination of two exponential parts. Moreover, the
resultant plots showed that there is strong correlation between the formula found in literature and the one derived on the basis of
the fit of data sets in this study. In addition, it was found that the biodistribution behaviors of the developed kit and the com-
mercial one were very close. The obtained results suggest that the developed DTPA has practically the same kinetics as the
commercial one.
Keywords: 99m-Technitium; Biodistribution; Data Fitting; DTPA; Modeling; Urinary Excretion Kinetics; CNESTEN
Introduction
Radiopharmaceuticals are radioactive compounds used for
imaging and diagnosis of human diseases. Some of the radio-
active are used for cancer therapy (about 5%).1, 2 A radio-
pharmaceutical has two components: a radionuclide and an
agent (the pharmaceutical), which directs the radionuclide to
a receptor antigen, ionic pump, or other site of interest within
the body. Some radiopharmaceuticals are simple, such as the
ionic form of the radionuclide, while most radiopharmaceu-
ticals have a complex chemical structure where the radionu-
clide provides a signal, indicating the site of localization of
the carrier molecule.2, 3
Diethylene triamine penta acetic acid (DTPA) is one of
pharmaceuticals. It used in different complexes for different
objective, for examples: [111In-DTPA-DPhe1] octreotide is
used for diagnostic stomastatin sintigraphy 4, 5, 6, 7, Diethylene
triamine penta acetic acid neolactosyl human serum albumin
labeled with technetium-99m (99mTc-DTPA-LSA kit) afford the
opportunity of hepatic receptor imaging.8 Diethylene tri-
amine penta acetate galactosyl human serum albumin (GSA)
is used as human hepatic asialoglycoprotein receptor-
binding radiopharmaceutical in Japan since 1992.8 In con-
stant, DTPA is an efficient candidate when it is radiolabeled
with a therapeutic radioisotope such as 177Lu or 90Y.9, 10, 11, 12
Although this molecule has a negligible bridging capacity.13 It
is used as a simple radiopharmaceutical (technetiated radio-
pharmaceutical). 99mTc-DTPA is the most commonly used
radiopharmaceutical for renography.14
The commercial DTPA kits are usually made of pentasodium
or calcium trisodium salt of DTPA (diethylene triamine penta
acetate. The freeze- dry kitcontains appropriate amounts of
stannous chloride dehydrate in lyophilized form. Radio-
labeling is performed by adding oxidant-free 99mTcO4- to the
kit vial and mixing. In this study, attempt was made to fit the
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obtained experimental data in order to establish the devel-
oped DTPA biodistribution mathematical model. Also, the
team had compared the behaviors of the developed kit
(DTPA-CNESTEN) and the commercial one (DTPA-ref).
Methods and Materials
Preparation of kit for 99mTc-DTPA
Reagents
- Ethylenediamine pentaacetic acid (DTPA)
- Stannous chloride dihydrate: SnCl2.2H20;
- Hydrochloric acid HCl;
- Sodium hydroxide: NaOH;
- Water for injection;
- Nitrogen gas.
Technitium-99m
Technetium-99m-pertechnitate was obtained from a commer-
cial 99mMo/99mTc generator (10 GBq) (schering/CIS- biointer-
national).
Gamma counter
The gamma counter used is NaI detector type COBRA 5002
from Packard.
Radiolabeling
Radiolabeling of DTPA-CNESTEN and the DTPA-ref, l, were
performed by reconstituting the freeze-dried kit using 5 mL
of freshly eluted 99mTcO4- solutions. The 99mTcO4- solutions
were eluted from 99mMo/99mTc generator containing a maxi-
mum of 40 mCi of activity. The 99mTc-DTPA labeled in this
manner should be stable for over 4 hours after labeling.15, 16
Animals
To evaluate tissue’s distributions characteristics of DTPA-
CNESTEN and DTPA-ref, biodistribution studies were per-
formed using male BALB/c mice, average weight about 50-60
g. The animals were carried from Pasteur Institute- Casa-
blanca. During this study, they were reared in our laboratory
and they had free access to food and water at all times. The
room temperature was about 20 °C.
Quality control
Radiochemical purity
Radiochemical purity (RCP) is an important quality parame-
ter for radiopharmaceuticals, as their radiochemical form
determines their biodistribution.14, 17 For this reason, the use
of radiopharmaceutical in vivo needs RCP testing to be car-
ried out just before administration to the patient.16, 18,19
To determine radiochemical purity labeling efficiency of the
product, European Pharmacopeia’s chromatographic method,
which is fast and easy, has been used.14 This method involves
ascending instant thin layer chromatography (ITLC). The
ITLC strips were utilized as the stationary phase and two
different solvent systems as indexed in European Pharmaco-
peia 2008. The procedure involved spotting about 2 µl sample
of 99mTc DTPA onto chromatography strips 10 cm in length.
After developing in the solvent, the strips were cut into two
portions and the activity in each portion was measured in the
form of counts using a gamma counter. The percentage ac-
tivity at the origin and the front were determined. The com-
plex 99mTc DTPA remained at the origin and free technetium
traveled with the solvent (methyl-ethyl- ketone MEK) front
(Rf = 0.9 - 1.0). The percentage of colloid was determined
using 0.9% solution of sodium chloride as the mobile phase
(the 99mTc-DTPA and TcO4- have about the same Rf in this
system). Complexes were successfully labeled (RCP > 95%)
and stable about 24 hours.
Biodistribution study
Biodistribution studies regroup almost all of studies using
radiopharmaceuticals. It is an important analytical step in
preclinical studies.20
After successful operations of radiolabeling, dilution (with
0.9% NaCl solution) to obtain a volumetric activity about 400
µCi / 5.4 mL and RCP was above 95%. Mice were weighed
and injected with 0.1 mL of the radiolabeled compound in the
tail vein. After injections, the animals were kept in separately
numbered beakers. And their urine was collected.
The injected activity is calculated by taking the difference
between the weight of the syringe before and after the injec-
tion. At the end of 2 min, 5 min, 15 min, 1 h and 2 h time
points, the animals were killed. They were dissected and
blood sample was first taken by heart puncture. Then the
other organs of interest were carefully dissected, placed in
individual disposable plastic tubes and accurately weighed.
The focus of this study was thyroid, blood, and urine. At least
three animals were studied at each time point. After killing
each mouse, the tail was removed and kept separately. The
activity in the organs and the tail were measured in the
gamma counter.
The total retained dose (%TRD) estimated as follows:% TRD(organ) = × 100
Where, “A” denotes the activity or counts in the organ of
interest and “B” represents the activity or counts in all organs
and the carcass except for the tail.
To accurately estimate the activity and to account for decay
corrections in the 99mTc activity, standard solutions of the
radiopharmaceuticals were prepared.
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Data Modeling
Radiopharmaceuticals administered to humans disappear
from the biological system through fecal or urinary excretion.
This biological disappearance follows a bi-exponential law 21,
22, expressed as: = + ( . 1)
where, “t” designate time, “a” and “c” the intercepts and “b”
and “d” are the slopes of the fast and the slow components of
the plasma disappearance curve.
In this work, the team used the Open Curve Fitting Tool
3.3.1, incorporated under the MATLAB R2013b platform 23,
to compute the best values of the exponential parameters a, b,
c and d with 95% confidence bounds. The optimal values of
these parameters correspond to the minimum of the mean
square error, which can be defined as the differences between
the original data y (response value) and the predicted re-
sponse value ŷ at each predictor value.
For both sets of data, the mean values of the parameters de-
fined above were calculated. The Table 1 below shows the
obtained values of the model parameters; whereas Figure 1
illustrates the plot of the experimental data and the corre-
sponding mathematical model.
TABLE 1: Parameter values of the bio-distribution data fitting model.
Biological
parts
Model Coefficients
MSEa b c d
Blood 14.23 -0.03257 0 -0.03257 2.7603
Urinary excretion 57.08 0.004396 -40.31 -0.06128 5.9184
Thyroid 0.4199 -0.01421 0 -0.01421 0.1542
(a)
(b)
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(c)
FIG. 1: Plot of the experimental data and the corresponding mathematical model in different biological parts. (a) Blood (b) Thyroid (c) Urinary
excretion.
FIG. 2: Comparison of the developed DTPA and the commercial one in blood.
The comparison of the results obtained for the developed
DTPA at the CNESTEN and the commercial one are illus-
trated in the Figure 2 below. This figure shows that the de-
veloped medicine has the same behavior as the commercial
one.
Conclusion
In this study, the team concluded that the biodistribution of
DTPA developed at the CNESTEN, can be modeled using a
combination of two exponential parts. In addition, the
graphics representations of the modeled data show that the
drug evolution in both thyroid and blood has an opposite
sense with its evolution in the urinary excretion. However,
the obtained results proved that the developed DTPA has
practically the same kinetics as the commercial one.
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